Renia Ahmed ’30
Alzheimer’s Disease (AD) is a progressive neurodegenerative disease and the most common cause of dementia, affecting millions of people worldwide. Amyloid plaques and tau protein tangles are pathological hallmarks of AD. Normally, tau proteins help maintain the internal structures that transport nutrients throughout neurons; however, during AD, tau becomes altered and forms tangled clumps, disrupting the transport system and contributing to neuronal dysfunction and death. Amyloid plaques are clumps of protein fragments called amyloid-beta that accumulate between neurons, disrupting communication and contributing to neuronal damage during AD. Together, amyloid plaques and tau protein tangles are associated with the progressive loss of memory and other cognitive abilities (Zhang et al., 2021). AD pathology is also accompanied by synaptic dysfunction, network disruption, neuroinflammation, and progressive neuronal degeneration, resulting in cognitive decline. Astrocytes have long been neglected in research on neurodegenerative diseases, yet their crucial role in the metabolic processes of the brain renders them vital to brain functioning. These star-shaped glial cells are crucial to synaptic regulation and eventually lose their function with the development of AD. Astrocytes can initially form the necessary responses to amyloid pathology; however, as pathology progresses, persistent inflammatory signaling and cellular stress can impair astrocytic metabolism, neurotransmitter uptake, calcium homeostasis, and synaptic support (Wang et al., 2023). Deep brain stimulation, whose modern clinical development arose during the 1980s, is an established treatment for several movement disorders, including Parkinson’s disease and is being actively investigated in clinical trials as a treatment for AD (Zhang et al., 2026). However, its limitations as a viable treatment for AD include invasive surgery, implanted hardware, limited symptom coverage, and patient-selection constraints. Deep brain stimulation does not cure or reverse underlying neurodegeneration, nor does it reliably halt the development of amyloid plaques and tau protein tangles (Mello et al., 2025). Furthermore, its efficacy for improving cognition in AD is uncertain, particularly in advanced disease, emphasizing the need for further research into alternative approaches (Xu et al., 2024). Optogenetics is a biological technique to control neuronal activity using genetically encoded light-sensitive proteins and provides greater cell-type and circuit-specific treatment. Wielding optogenetics offers a unique solution to discovering the mechanisms and slowing the development of AD via cell-type-specific research. By specifically targeting astrocytes, optogenetics may offer a novel approach to restoring the neural circuitry and cellular communication disrupted by AD.
Figure 1. Interaction between different types of cells contributing to the progress of AD pathogenesis
Note. Antioxidants (Basel). Mitroshina, E., Kalinina, E., & Vedunova, M. (2023). Optogenetics in Alzheimer’s Disease: Focus on Astrocytes. Antioxidants (Basel, Switzerland), 12(10), 1856. https://doi.org/10.3390/antiox12101856
Calcium signaling is crucial to a myriad of functions in the human body. Astrocytes use intracellular calcium signaling as an important method of communication and by doing so allow for gliotransmitter release, synapse control for neurons, and blood flow in the brain. Astrocytic calcium signaling is dysregulated in AD models, although the direction of this change is not uniform in research. Some studies report pathological calcium hyperactivity while others report reduced calcium activity at specific disease stages (Khakh et al., 2015). These differences may reflect disease stage, brain region, and the type of calcium activity measured, suggesting that effective interventions should aim to restore physiologically appropriate signaling rather than simply increase or suppress astrocytic activity. Due to hyperactivity near plaques and general hypoactivity, astrocytes are not able to appropriately respond to restore the neuronal network to homeostasis. Astrocytes contribute to the regulation of maintaining slow-wave oscillations which are rhythmic alterations in the cortical neuronal membrane potential that lies between a silent hyperpolarized state and an active firing state that define sleep (Poskanzer et al., 2016). Astrocytes are able to maintain these slow-wave oscillations by controlling extracellular ion levels, releasing gliotransmitters, and engaging in bidirectional signaling with neuronal networks (Sriram et al., 2024). However, the disruption of slow-wave oscillations occurs early in AD pathology as the loss of slow-wave sleep has been associated with the brain’s ability to clear metabolic waste, which in turn accelerates amyloid and tau accumulation.
To selectively manipulate astrocytes, researchers can use viral vectors or genetically engineered animal models to express light-sensitive proteins such as channelrhodopsin in astrocytes. Scientists can use channelrhodopsin-2 (ChR2) to flash light specifically at astrocytes in the brain, resulting in selective modulation of astrocytic activity to restore a specific impaired function. ChR2 responds to specific wavelengths of light, and researchers can therefore use precisely timed illumination to alter the activity of these cells, enabling astrocytes to be manipulated without directly expressing the opsin in neighboring neurons (Mitroshina et al., 2023). This cellular specificity makes optogenetics particularly useful for investigating whether astrocyte dysfunction is a cause or consequence of AD pathology. Restoring specific aspects of astrocytic function using optogenetics in amyloid-based mouse models has the potential to reduce several pathological and functional abnormalities in two ways.
First, restoring astrocytic activity could help recover disrupted brain oscillations. Slow-wave and gamma oscillations coordinate communication across neuronal populations and are essential for processes such as memory. Optogenetic activation of cortical astrocytes at the endogenous slow-wave frequency (0.6 Hz) restores slow-wave power in AD mouse models. In an article published August 2023 in Scientific Reports, researchers found that targeting astrocytes via optogenetics resulted in a return to normal slow-wave oscillations in an AD mouse model (Lee et al., 2023). In a study from 2019, 1.2 Hz optogenetic stimulation of cortical pyramidal neurons had negative effects, including increased amyloid production, disrupted neuronal calcium homeostasis, and reduced synaptic spines (Kastanenka, 2019). Although research has demonstrated that optogenetic manipulation of astrocytes can restore slow-wave activity in an AD mouse model, it remains unknown whether the process can restore physiologically coordinated slow-wave activity across larger brain networks.
Second, optogenetic targeting of astrocytes may enable neuronal calcium homeostasis to be restored. In APP mice, astrocyte-targeted optogenetic stimulation reduced pathological elevations in neuronal calcium and partially restored neuronal calcium homeostasis (Lee et al., 2023). The rhythmic activation also decreased beta-amyloid deposition and preserved functional neural network architecture. Restoring calcium signals could be crucial to reestablishing the communication between astrocytes and neurons that is necessary for healthy synaptic function. This approach would target the cellular dysfunction that makes neural circuits increasingly vulnerable to Alzheimer’s pathology.
A possible combination of treatment, as an accessory to optogenetic therapy, furthermore has the potential to transform Alzheimer’s treatment. Viral vector targeting of the JAK-STAT3 signaling pathway has been shown in mouse models to reduce amyloid plaque development and improve impaired synaptic plasticity. A complementary strategy could target the molecular machinery underlying astrocytic calcium dysfunction. For example, astrocyte-specific overexpression of STIM1 has also been shown to restore normal astrocytic calcium homeostasis. A 2023 Nature Communications study found reduced astrocytic STIM1 and calcium signaling in female mice while astrocyte-specific STIM1 overexpression restored calcium signaling and astrocyte-dependent synaptic plasticity (Lia et al., 2023). These findings raise the possibility that astrocyte-targeted neuromodulation could slow specific pathological features of AD, but substantial research is required before this approach can be considered a therapeutic strategy for humans.
Three main barriers still present different challenges to slowing AD development in humans. Much of the current evidence comes from mouse models, which reproduce only certain aspects of human AD. A therapy that successfully restores astrocytic activity in mice may therefore produce different effects in the human brain. Second, delivering light to the human brain regions is a physical process that is challenging. Direct application in the human brain remains in the preclinical stage due to the invasiveness of light delivery and the challenges posed by the blood-brain barrier to viral-vector delivery; however, recent clinical milestones in human optogenetic gene therapies for retinal disease demonstrate that light-sensitive gene therapies have the possibility to move toward clinical translation (Sahel et al., 2021). Lastly, optogenetics requires introducing light-sensitive proteins into specific cells; hence, the safety and precision of viral-vector delivery would have to be established before clinical use (Shen et al., 2020).
AD cannot be understood solely through the destruction of neurons. As evidence increasingly reveals the importance of astrocytes in maintaining synaptic function, metabolism, calcium signaling, and neuronal oscillations, these cells may represent an overlooked therapeutic target. The interactions between neurons and astrocytes are complex, and this interdisciplinary research has the potential to unravel the mysteries of AD.
Renia Ahmed is a staff writer at The Princeton Medical Review. She can be reached at ra0261@princeton.edu.
References
Kastanenka, K.V., Calvo-Rodriguez, M., Hou, S.S. et al. Frequency-dependent exacerbation of Alzheimer’s disease neuropathophysiology. Sci Rep 9, 8964 (2019). https://doi.org/10.1038/s41598-019-44964-z
Khakh, B. S., & McCarthy, K. D. (2015). Astrocyte calcium signaling: from observations to functions and the challenges therein. Cold Spring Harbor perspectives in biology, 7(4), a020404. https://doi.org/10.1101/cshperspect.a020404
Lee, Y.F., Russ, A.N., Zhao, Q. et al. Optogenetic targeting of astrocytes restores slow brain rhythm function and slows Alzheimer’s disease pathology. Sci Rep 13, 13075 (2023). https://doi.org/10.1038/s41598-023-40402-3
Lia, A., Sansevero, G., Chiavegato, A., Sbrissa, M., Pendin, D., Mariotti, L., Pozzan, T., Berardi, N., Carmignoto, G., Fasolato, C., & Zonta, M. (2023). Rescue of astrocyte activity by the calcium sensor
STIM1 restores long-term synaptic plasticity in female mice modelling Alzheimer’s disease. Nature Communications, 14, 1590. https://doi.org/10.1038/s41467-023-37240-2
Mello, Julia Scaramal, Gabriela Ilias Bechara, Paulo Henrique Pires de Aguiar, Effectiveness of DBS as a treatment for Alzheimer’s disease: Meta-analysis, Deep Brain Stimulation, Volume 8, 2025, Pages 15-19, ISSN 2949-6691, https://doi.org/10.1016/j.jdbs.2025.01.001.
Mirzayi, P., Shobeiri, P., Kalantari, A., Perry, G., & Rezaei, N. (2022). Optogenetics: implications for Alzheimer’s disease research and therapy. Molecular brain, 15(1), 20. https://doi.org/10.1186/s13041-022-00905-y
Mitroshina, E., Kalinina, E., & Vedunova, M. (2023). Optogenetics in Alzheimer’s Disease: Focus on Astrocytes. Antioxidants (Basel, Switzerland), 12(10), 1856. https://doi.org/10.3390/antiox12101856
Poskanzer, K. E., & Yuste, R. (2016). Astrocytes regulate cortical state switching in vivo. Proceedings of the National Academy of Sciences of the United States of America, 113(19), E2675–E2684. https://doi.org/10.1073/pnas.1520759113
Ransohoff, R. M. (2016). How neuroinflammation contributes to neurodegeneration. Science, 353(6301), 777–783. https://doi.org/10.1126/science.aag2590
Ries, M., & Sastre, M. (2016). Mechanisms of Aβ clearance and degradation by glial cells. Frontiers in Aging Neuroscience, 8, 160. https://doi.org/10.3389/fnagi.2016.00160
Sahel, JA., Boulanger-Scemama, E., Pagot, C. et al. Partial recovery of visual function in a blind patient after optogenetic therapy. Nat Med 27, 1223–1229 (2021). https://doi.org/10.1038/s41591-021-01351-4
Science. (n.d.). Can adding light sensors to nerve cells switch pain, epilepsy, and other disorders? https://www.science.org/content/article/can-adding-light-sensors-nerve-cells-switch-pain-epilepsy-and-other-disorders
Shen, Y., Campbell, R. E., Côté, D. C., & Paquet, M. E. (2020). Challenges for Therapeutic Applications of Opsin-Based Optogenetic Tools in Humans. Frontiers in neural circuits, 14, 41. https://doi.org/10.3389/fncir.2020.00041
Sriram S, Carstens K, Dewing W and Fiacco TA (2024) Astrocyte regulation of extracellular space parameters across the sleep-wake cycle. Front. Cell. Neurosci. 18:1401698. doi: 10.3389/fncel.2024.1401698
Tiwari, P., & Tolwinski, N. S. (2023). Using Optogenetics to Model Cellular Effects of Alzheimer’s Disease. International journal of molecular sciences, 24(5), 4300. https://doi.org/10.3390/ijms24054300
Vann, K. T., & Xiong, Z. G. (2016). Optogenetics for neurodegenerative diseases. International journal of physiology, pathophysiology and pharmacology, 8(1), 1–8.
Wang, Y., et al. (2023). Microglia and astrocytes in Alzheimer’s disease: Significance and summary of recent advances. Journal of Alzheimer’s Disease, 94(4), 1127–1152. https://doi.org/10.14336/AD.2023.0907
Xu, J., Liu, B., Feng, Z., Yu, X., Shang, G., Liu, Y., Sun, Y., Yang, H., Chen, Y., Zhang, Y., & Mao, Z. (2024). Deep brain stimulation versus nonsurgical treatment for severe Alzheimer’s disease: A long-term retrospective cohort study. Journal of Alzheimer’s disease reports, 8(1), 1677–1689. https://doi.org/10.1177/25424823241297852
Zhang, H., Wei, W., Zhao, M., Ma, L., Jiang, X., Pei, H., Cao, Y., & Li, H. (2021). Interaction between Aβ and Tau in the Pathogenesis of Alzheimer’s Disease. International journal of biological sciences, 17(9), 2181–2192. https://doi.org/10.7150/ijbs.57078
Zhang, Q., Li, T., Xu, M., Islam, B., & Wang, J. (2024). Application of Optogenetics in Neurodegenerative Diseases. Cellular and molecular neurobiology, 44(1), 57. https://doi.org/10.1007/s10571-024-01486-1
Zhang, F., Meng, Y., & Zhang, W. (2026). Deep brain stimulation for the treatment of Alzheimer’s disease: A safer and more effective strategy. Neural regeneration research, 21(5), 1899–1909. https://doi.org/10.4103/NRR.NRR-D-24-01088

Leave a Reply